Przebieg i wyniki leczenia chorych na rozlanego chloniaka (DLBCL) żolądka

Abstract

Author(s): Elżbieta Starosławska, Aneta Dobrzyńska-Rutkowska, Anna Twardosz, Maria Luiza Kusz, Iwona Hus, Maria Mazurkiewicz

It is still under discussion what is the optimal treatment of primary gastric diffuse large Bcell lymphoma (PG-DLBCL). Currently, an antracyclins-based chemotherapy combined with rituximab is thought to facilitate complete remission without the need for a surgical intervention. The course and results of the treatment of patients suffering from primary gastric diffuse large B-cell lymphoma in the Centre of Oncology of Lubelska Land in the period 2003-2010 have been presented. 7 patients were enrolled in the study, with four of them subject to initial surgical treatment and six – to immunochemotherapy under the R-CHOP-21 regime. Only one subject included in the study underwent CHOP chemotherapy. In all patients complete remission (CR) was achieved and sustained from 79 to 3 months.

Share this article

Editors List

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)

  • Skowronska-Gardas

    Department of Radiotherapy, Oncology Center-Institute (Warsaw, Poland)

  • Serban-Dan Costa

    Head of the Obstetrics and Gynecology Clinic of the University of Otto von Guericke (Magdeburg, Germany)